Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization

Tao Zuo,1,2,3,* Fen Zhang,1,2,3,* Grace C. Y. Lui3,4,5 Yun Kit Yeoh,1,5 Amy Y. L. Li,3 Hui Zhan,1,2,3 Yating Wan,1,2,3 Arthur C. K. Chung,1,2,3 Chun Pan Cheung,1,2,3 Nan Chen,1,2,3 Christopher K. C. Lai,5 Zigui Chen,5 Eugene Y. K. Tso,6 Kitty S. C. Fung,7 Veronica Chan,6 Lowell Ling,8 Gavin Joynt,8 David S. C. Hui,3,4 Francis K. L. Chan,1,3 Paul K. S. Chan,1,5 and Siew C. Ng1,2,3

1Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China; 2State Key Laboratory for Digestive Disease, Institute of Digestive Disease, Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Shatin, Hong Kong, China; 3Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China; 4Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, Hong Kong, China; 5Department of Microbiology, The Chinese University of Hong Kong, Shatin, Hong Kong, China; 6Department of Medicine and Geriatrics, United Christian Hospital, Hong Kong, China; 7Department of Pathology, United Christian Hospital, Hong Kong, China; and 8Department of Anaesthesia and Intensive Care, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China

BACKGROUND & AIMS: Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects gastrointestinal tissues, little is known about the roles of gut commensal microbes in susceptibility to and severity of infection. We investigated changes in fecal microbiomes of patients with SARS-CoV-2 infection during hospitalization and associations with severity and fecal shedding of virus. METHODS: We performed shotgun metagenomic sequencing analyses of fecal samples from 15 patients with Coronavirus Disease 2019 (COVID-19) in Hong Kong, from February 5 through March 17, 2020. Fecal samples were collected 2 or 3 times per week from time of hospitalization until discharge; disease was categorized as mild (no radiographic evidence of pneumonia), moderate (pneumonia was present), severe (respiratory rate ≥30/min, or oxygen saturation <93% when breathing ambient air), or critical (respiratory failure requiring mechanical ventilation, shock, or organ failure requiring intensive care). We compared microbiome data with those from 6 subjects with community-acquired pneumonia and 15 healthy individuals (controls). We assessed gut microbiome profiles in association with disease severity and changes in fecal shedding of SARS-CoV-2. RESULTS: Patients with COVID-19 had significant alterations in fecal microbiomes compared with controls, characterized by enrichment of opportunistic pathogens and depletion of beneficial commensals, at time of hospitalization and at all time-points during hospitalization. Depleted symbionts and gut dysbiosis persisted even after clearance of SARS-CoV-2 (determined from throat swabs) and resolution of respiratory symptoms.
Coronavirus Disease 2019 (COVID-19) is a respiratory illness caused by a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) and more than 3.3 million people worldwide have been infected as of May 1, 2020. Although most cases of COVID-19 are mild, disease can be severe, resulting in hospitalization, respiratory failure, or death. Early reports from Wuhan showed that 2% to 10% of patients with COVID-19 had gastrointestinal (GI) symptoms, including diarrhea, but a recent meta-analysis reported that up to 20% had GI symptoms. Studies have detected SARS-CoV-2 virus in anal swabs and stool samples in almost 50% of patients with COVID-19, suggesting that the digestive tract might be an extrapulmonary site for virus replication and activity. Moreover, fecal calprotectin was found to be elevated in patients with COVID-19 with diarrhea, an indicator of inflammatory responses in the gut. SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) receptor to enter the host, and this receptor is highly expressed in both the respiratory and GI tracts. ACE2 is important in controlling intestinal inflammation and gut microbial ecology. With trillions of diverse bacteria dwelling in our gut, the gut microbiome has a myriad of effects on gene regulation of immune response and metabolism. The commensal microbiota ecosystem in the gut is dynamic and can be regulated by invading viruses to facilitate a stimulatory or suppressive response. Studies have shown that respiratory viral infections may be associated with altered gut microbiome, which predispose patients to secondary bacterial infections. Recent meta-transcriptome sequencing of bronchoalveolar lavage fluid showed that the microbiota in SARS-CoV-2–infected patients was dominated by pathogens or oral and upper respiratory commensal bacteria. In addition, comorbidities commonly associated with severe COVID-19 are known to be associated with alterations in bacteria taxa from the phyla Bacteroidetes and Firmicutes, which were reported to regulate ACE2 expression in rodents. There is an urgent need to understand host microbial perturbations that underlie SARS-CoV-2 infection, which may affect response to infection and efficacy of various future immune interventions, such as vaccines.

In this pilot study, we hypothesize that the intestinal microbiota is altered in SARS-CoV-2 infection and is associated with susceptibility to severe disease. We prospectively included 15 hospitalized patients with COVID-19 admitted between February 16, 2020, and March 2, 2020, in Hong Kong, China, followed from hospital admission until discharge. Through the application of deep shotgun metagenomics, we investigated longitudinal changes of the gut microbiome in COVID-19.

Methods

Study Subject and Design

This prospective study involved 15 patients with COVID-19 hospitalized with laboratory-confirmed SARS-CoV-2 infection, 6 patients hospitalized with community-acquired pneumonia (pneumonia controls), and 15 healthy individuals (healthy controls) (Table 1, Supplementary Table 1, Figure 1).

WHAT YOU NEED TO KNOW

BACKGROUND AND CONTEXT

SARS-CoV-2 infects gastrointestinal tissues. The authors investigated changes in fecal microbiomes of patients with SARS-CoV-2 infection during hospitalization and associations with severity and fecal shedding of virus.

NEW FINDINGS

Fecal microbiomes from patients with COVID-19 had depletion of symbionts and enrichment of opportunistic pathogens, which persisted after clearance of SARS-CoV-2. Baseline microbiome composition associated with COVID-19 severity. Multiple species from the Bacteroides phylum correlated inversely with fecal shedding of SARS-CoV-2.

LIMITATIONS

This was a pilot exploratory study of 15 patients with COVID-19; further studies are needed of alterations in intestinal microbiomes of these patients over time.

IMPACT

These findings indicate the prolonged effect of SARS-CoV-2 infection on the gut microbiomes of patients with COVID-19. Strategies to alter the gut microbiome might be developed to manage gastrointestinal effects of the virus in these patients.

Abbreviations used in this paper: ACE2, angiotensin-converting enzyme 2; COVID-19, coronavirus disease 2019; GI, gastrointestinal; RT-PCR, reverse-transcriptase polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
SARS-CoV-2 infection was confirmed by 2 consecutive reverse-transcriptase polymerase chain reaction (RT-PCR) tests targeting different regions of the RdRp gene performed by the local hospital and Public Health Laboratory Service. Pneumonia controls were patients admitted with community-acquired pneumonia tested negative for SARS-CoV-2 PCR on 2 respiratory samples. Patients with COVID-19 and pneumonia controls were admitted to the Prince of Wales Hospital or the United Christian Hospital, Hong Kong. Healthy controls were individuals with no past medical history or history of antibiotic intake in the past 3 months recruited via advertisement from the general population and tested negative for SARS-CoV-2. All subjects were recruited between February 5 and March 17, 2020. Severity of COVID-19 infection was categorized as (1) mild, if there was no radiographic evidence of pneumonia; (2) moderate, if pneumonia was present along with fever and respiratory tract symptoms; (3) severe, if respiratory rate ≥30/min, oxygen saturation ≤93% when breathing ambient air, or PaO2 / FiO2 ≤300 mm Hg (1 mm Hg = 0.133 kPa); or (4) critical, if there was respiratory failure requiring mechanical ventilation, shock, or organ failure requiring intensive care.23 This study was approved by the Joint Chinese University of Hong Kong–New Territories East Cluster Clinical Research Ethics Committees (2020.076). All patients provided informed consent to participate in this study. Data including demographics, laboratory results, imaging results, and medical therapy were extracted from the electronic medical records in the Hong Kong Hospital Authority clinical management system. Fecal samples from patients with COVID-19 were collected serially 2 to 3 times per week until discharge. This study was conducted in accordance with the Declaration of Helsinki.

Detection of Fecal SARS-CoV-2 Viral Load

SARS-CoV-2 viral loads in stool were measured using real-time RT-PCR assay. Viral RNA from stool samples was extracted using QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany); 0.1 g of stool was suspended in 1 mL of viral transport medium (in 1:10 dilution) and centrifuged for 20 minutes at 4000 g. An 140-μL aliquot of the filtrate was used as starting material following the manufacturer’s protocol. SARS-CoV-2 RNA was quantified using real-time RT-PCR. The primer-probe set N1 (2019-nCoV_N1-F: 5ʹ-GAC CCC AAA ATC AGC GAA AT-3ʹ, 2019-nCoV_N1-R: 5ʹ-TCT GGT TAC TGC CAG TTG AAT CTG-3ʹ, and 2019-nCoV_N1-P: 5ʹ-FAM-ACC CCG CAT TAC GTT TGG ACC-BHQ1-3ʹ) designed by US Centers for Disease Control and Prevention were purchased from Integrated DNA Technologies (Coralville, IA). The 1-step real-time RT-PCR reaction contained 10 μL of the extracted preparation, 4 μL TaqMan Fast Virus 1-Step Master Mix (Applied Biosystems, Foster City, CA) in a final reaction volume of 20 μL. The primer and probe concentration were 0.5 μM and 0.125 μM, respectively. The cycling conditions, 25°C for 2 minutes, 50°C for 15 minutes, 95°C for 2 minutes, followed by 45 cycles of 95°C for

| Table 1. Subject Characteristics |
|--------------------------------|
| Variables | COVID-19 cases | Pneumonia controls | Healthy controls |
| Number | 15 | 6 | 15 |
| Male | 15 (47) | 4 (67) | 0 (0) |
| Median age, y (IQR) | 55 (44, 67.5) | 50 (44, 69) | 48 (45, 48) |
| Comorbidities, n (%) | 6 (40) | 6 (100) | 0 (0) |
| Recent exposure history, n (%) | 1 (7) | 0 (0) | 0 (0) |
| Travel to cities of Hubei province | 1 (7) | 0 (0) | 0 (0) |
| Contact with person with COVID-19 | 5 (33) | 0 (0) | 0 (0) |
| Have family cluster outbreak | 4 (27) | 0 (0) | 0 (0) |
| Symptoms at admission, n (%) | 9 (60) | 4 (67) | 0 (0) |
| Fever | 9 (60) | 4 (67) | 0 (0) |
| Gastrointestinal symptoms | 1 (7) | 2 (33) | 0 (0) |
| Diarrhea | 1 (7) | 2 (33) | 0 (0) |
| Respiratory symptoms | 11 (73) | 4 (67) | 0 (0) |
| Cough | 11 (73) | 4 (67) | 0 (0) |
| Sputum | 5 (33) | 3 (50) | 0 (0) |
| Rhinorrhea | 3 (20) | 1 (17) | 0 (0) |
| Shortness of breath | 4 (27) | 3 (50) | 0 (0) |
| Blood result | | | |
| Lymphocyte counts (x 10⁹/L, normal range 1.1–2.9) | 0.9 (0.7, 1.1) | 1.1 (0.9, 1.2) | 0 (0) |
| Antibiotic therapy at presentation, n (%) | 7 (47) | 6 (100) | 0 (0) |
| Amoxycillin Clavulanate | 4 (27) | 3 (50) | 0 (0) |
| Cephalosporin | 5 (33) | 3 (50) | 0 (0) |
| Tetracycline | 4 (27) | 3 (50) | 0 (0) |
| Antiviral therapy, n (%) | 13 (87) | 0 (0) | 0 (0) |
| Lopinavir-Ritonavir | 13 (87) | 0 (0) | 0 (0) |
| Ribavirin | 7 (47) | 0 (0) | 0 (0) |
| Interferon beta-1b | 1 (7) | 0 (0) | 0 (0) |
| Death, n (%) | 0 (0) | 0 (0) | 0 (0) |

NOTE. Values are expressed in number (percentage) and median (interquartile range).
15 seconds, and 55°C for 30 seconds, were performed with the StepOnePlus Real-Time PCR System (Applied Biosystems). The cycle threshold values of real-time RT-PCR were converted into viral RNA copies based on a standard curve prepared from 10-fold serial dilutions of known copies of plasmid containing the full N gene (2019-nCoV_N_Positive Control; Integrated DNA Technologies). Samples were considered as negative if the cycle threshold values exceeded 39.9 cycles. The detection limit of real-time RT-PCR was 347 copies/mL.

**Microbial Profiling of Fecal Samples With Metagenomic Sequencing**

An approximately 0.1 g fecal sample was prewashed with 1 mL double-distilled H2O and pellet by centrifugation at 13,000g for 1 minute. The fecal DNA was subsequently extracted from the pellet using Maxwell RSC PureFood GMO and Authentication Kit (Promega, Madison, WI) following the manufacturer’s instructions. Briefly, the fecal pellet was added to 1 mL of CTAB buffer and vortexed for 30 seconds, then the sample was heated at 95°C for 5 minutes. After that, the samples were vortexed thoroughly with beads at maximum speed for 15 minutes. Then, 40 µL of proteinase K and 20 µL of RNase A was added to the sample and the mixture was incubated at 70°C for 10 minutes. The supernatant was then obtained by centrifuging at 13,000g for 5 minutes and was added into the Maxwell RSC machine for DNA extraction. Extracted DNA was subject to DNA libraries construction, completed through the processes of end repairing, adding A to tails, purification and PCR amplification, using Nextera DNA Flex Library Preparation kit (Illumina, San Diego, CA). Libraries were subsequently sequenced on our in-house sequencer Illumina NextSeq 550 (150 base pairs paired-end) at the Center for Microbiota Research, The Chinese University of Hong Kong. Raw sequence reads were filtered and quality-trimmed using Trimmomatic v0.36 as follows: (1) trimming low-quality base (quality score <20); (2) removing reads shorter than 50 base pairs; (3) removing sequencing adapters. Contaminating human reads were filtering using Kneaddata (Reference database: GRCh38.p12) with default parameters. Profiling of bacterial communities was performed using MetaPhlAn2 (V2.9) by mapping reads to clade-specific markers.

**Statistical Analysis**

Relative abundance data from MetaPhlAn2 were imported into R v3.5.1. Nonmetric multidimensional scaling analyses were performed on all baseline fecal microbiomes between groups, and serial fecal microbiomes in each COVID-19 case during the disease course, based on Bray-Curtis dissimilarities using vegan package (v2.5-3). Differential bacterial taxa between patients with COVID-19 (with or without antibiotics treatment at inclusion), patients with community-acquired pneumonia, and healthy controls were identified using

---

**Figure 1.** Schematic diagram of stool sample collection, SARS-CoV-2 PCR test results and hospitalization duration in patients with COVID-19 (n = 15). “CoV” denotes patient with COVID-19. Stool specimens were serially collected for shotgun metagenomics sequencing and quantitative RT-PCR test for SARS-CoV-2 virus; “D0” denotes baseline date when the first stool was collected after hospitalization; the following timepoints starting with “D” represent days since baseline stool collection. “+ve throat swab”: the first positive result for SARS-CoV-2 virus in nasopharyngeal/throat/pooled swabs; “-ve throat swab”: the first negative result for SARS-CoV-2 virus in 2 consecutive negative nasopharyngeal/throat/pooled swab tests, on which patient was then discharged.
| Gut microbiome feature | Taxon | Group | Coefficient | P value | Q value |
|------------------------|-------|-------|-------------|---------|---------|
| **COVID-19 (antibiotics naïve: abx –)** | | | | | |
| Specifically enriched in viscosus | p_Acinetobacter| COVID-19 (Abx –) | 0.243 | 8.2E-08 | 6.4E-05 |
| Underrepresented in COVID-19 and pneumonia | p_Firmicutes| COVID-19 (Abx –) | -0.280 | 1.2E-04 | 2.5E-02 |
| **COVID-19 (antibiotics exposed: abx +)** | | | | | |
| Underrepresented in COVID-19 | p_Firmicutes| COVID-19 (Abx +) | -0.812 | 2.6E-05 | 0.00853 |
| Underrepresented in both COVID-19 and pneumonia | p_Firmicutes| COVID-19 (Abx +) | -0.300 | 2.0E-04 | 0.03709 |
| Underrepresented in both COVID-19 and pneumonia | p_Firmicutes| COVID-19 (Abx +) | -0.903 | 1.7E-04 | 0.03316 |
| Pneumonia patients | | | | | |
| Underrepresented in pneumonia | p_Bacteroides| Pneumonia | -0.256 | 3.5E-04 | 0.03539 |
| Underrepresented in both COVID-19 and pneumonia | p_Firmicutes| Pneumonia | 0.228 | 5.0E-05 | 0.01261 |

*Table 2. Gut Microbiome Features in Patients With COVID-19*
Multivariate Association with Linear Models (MaAsLin). Spearman correlation analyses were conducted to associate baseline microbiome profiles of 7 antibiotics-naïve patients at baseline with COVID-19 severity, and to associate longitudinal fecal SARS-CoV-2 loads with timepoint-matched bacterial profiles across all 15 patients with COVID-19, while adjusting for confounding factors.

Data Availability
Metagenomics Sequencing dataset was deposited to the National Center for Biotechnology Information Sequence Read Archive under BioProject accession number PRJNA624223.

Results
Fecal Microbiome Alterations in COVID-19
Among the 15 patients with COVID-19, 7 were antibiotics-naïve (COVID-19[abx−]) and 8 received empirical antibiotics (COVID-19[abx+]) at baseline (defined as date of the first stool collection after hospitalization). The median ages of patients with COVID-19, pneumonia controls, and healthy controls were 55, 50, and 48 years, respectively; 40% and 100% of patients with COVID-19 and pneumonia controls, respectively, had underlying comorbidities (Table 1, Supplementary Table 1). All patients with COVID-19 presented with respiratory symptoms but only 1 had diarrhea at presentation. None of the patients developed GI symptoms during hospitalization. Median duration of hospitalization was 21 ± 2.4 days (mean ± SE) in COVID-19 and pneumonia cases.

To understand alterations of the gut microbiome that underlie SARS-CoV-2 infection, we compared baseline fecal microbiome of patients with COVID-19 with healthy controls and pneumonia controls adjusting for age, gender, antibiotic use, and comorbidities. Antibiotic-naïve patients with COVID-19 were enriched in opportunistic pathogens known to cause bacteremia, including Clostridium hathewayi, Actinomyces viscosus, and Bacteroides nordii compared with controls (Table 2). COVID-19(abx+) patients demonstrated a further depletion of multiple bacterial species, which are symbionts beneficial to host immunity including Faecalibacterium prausnitzii, Lachnospiraceae bacterium 5_1_63F AA, Eubacterium rectale, Ruminococcus obeum, and Dorea formicicgenerans compared with COVID-19(abx−) patients (Table 2). Regardless of antibiotic use, underrepresented bacterial species in patients with COVID-19 were consistently absent or present at very low abundance during the disease course, even when SARS-CoV-2 virus was cleared from the nasopharyngeal swab and stool, and respiratory symptoms had resolved (Supplementary Figures 1–6).

Among all host factors, COVID-19 infection showed the largest effect size in affecting the gut microbiome (PERMANOVA test, $R^2 = 0.066, P = .002$, Figure 2A), followed by hyperlipidemia, pneumonia, and antibiotics, whereas age and gender showed no significant effects on gut microbiome alterations (Figure 2A). At the whole microbiome community level, healthy subjects’ fecal microbiome clustered together, whereas that of COVID-19(abx−) patients...
Table 3. Correlation of Gut Bacteria With COVID-19 Severity

| Correlation with COVID-19 severity | Bacteria taxa | Correlation coefficient | P value |
|-----------------------------------|--------------|-------------------------|---------|
| Positive                          |              |                         |         |
| p__Firmicutes/c__Erysipelotrichia/o__Erysipelotrichales/j__Erysipelotrichaceae/g__Coprobacillus | 0.92         | .003                   |
| p__Firmicutes/c__Erysipelotrichia/o__Erysipelotrichales/j__Erysipelotrichaceae/g__Erysipelotrichaceae_noname/o__Clostridium_ramosum | 0.92         | .003                   |
| p__Firmicutes/c__Erysipelotrichia/o__Erysipelotrichales/j__Erysipelotrichaceae/g__Clostridium_hatheway | 0.90         | .005                   |
| p__Firmicutes/c__Erysipelotrichia/o__Erysipelotrichales/j__Erysipelotrichaceae/g__Erysipelotrichaceae_noname | 0.90         | .006                   |
| p__Actinobacteria/c__Actinobacteria/o__Actinomycetales/j__Actinomycetaceae/g__Actinomyces/s__Actinomyces_odontolyticus | 0.87         | .011                   |
| p__P__Firmicutes/c__Erysipelotrichia/o__Erysipelotrichales/j__Erysipelotrichaceae/g__Erysipelotrichaceae_noname | 0.87         | .011                   |
| p__Firmicutes/c__Erysipelotrichia/o__Erysipelotrichales/j__Erysipelotrichaceae/g__Erysipelotrichaceae_noname | 0.87         | .011                   |
| Negative                          |              |                         |         |
| p__P__Actinobacteria/c__Actinobacteria/o__Bifidobacteriales/j__Bifidobacteriaceae/g__Bifidobacterium/s__Bifidobacterium_pseudocatenulatum | -0.81        | .026                   |
| p__P__Firmicutes/c__Clostridia/o__Clostridiales/j__Lachnospiraceae/g__Dorea/s__Dorea_longicatena | -0.81        | .026                   |
| p__P__Bacteroidetes/c__Bacteroidia/o__Bacteroidales/j__Parabacteroidaceae/g__Parabacteroides/s__Parabacteroides_unclassified | -0.81        | .029                   |
| p__P__Bacteroidetes/c__Bacteroidia/o__Bacteroidales/j__Rikenellaceae/g__Alistipes/s__Alistipes_indistinctus | -0.81        | .029                   |
| p__Proteobacteria/c__Gammaproteobacteria/o__Enterobacteriales/j__Enterobacteriaceae/g__Enterobacter/s__Enterobacter_cloacae | 0.87         | .011                   |
| p__P__Proteobacteria/c__Gammaproteobacteria/o__Enterobacteriales/j__Enterobacteriaceae/g__Enterobacter/s__Enterobacter_cloacae | 0.87         | .011                   |
| p__P__Bacteroidetes/c__Bacteroidia/o__Bacteroidales/j__Porphyromonadaceae/g__Parabacteroides/s__Parabacteroides_unclassified | 0.81         | .029                   |
| p__P__Bacteroidetes/c__Bacteroidia/o__Bacteroidales/j__Rikenellaceae/g__Alistipes/s__Alistipes_indistinctus | 0.81         | .029                   |
| p__Firmicutes/c__Clostridia/o__Clostridiales/j__Lachnospiraceae/g__Dorea | -0.81        | .026                   |
| p__Bacteroidetes/c__Bacteroidia/o__Bacteroidales/j__Lachnospiraceae/g__Bacteroides/s__Bacteroides_ovatus | -0.84         | .019                   |
| p__P__Firmicutes/c__Clostridia/o__Clostridiales/j__Lachnospiraceae/g__Anaerostipes/s__Anaerostipes_hadrus | -0.87         | .011                   |
| p__P__Firmicutes/c__Clostridia/o__Clostridiales/j__Lachnospiraceae/g__Bacteroides/s__Bacteroides_ovatus | -0.84         | .019                   |
| p__P__Firmicutes/c__Clostridia/o__Clostridiales/j__Lachnospiraceae/g__Anaerostipes/s__Anaerostipes_hadrus | -0.87         | .011                   |
| p__P__Firmicutes/c__Clostridia/o__Clostridiales/j__Lachnospiraceae/g__Bacteroides/s__Bacteroides_ovatus | -0.84         | .019                   |
| p__Firmicutes/c__Clostridia/o__Clostridiales/j__Lachnospiraceae/g__Alistipes/s__Alistipes_indistinctus | -0.81        | .026                   |
| p__P__Firmicutes/c__Clostridia/o__Clostridiales/j__Lachnospiraceae/g__Alistipes/s__Alistipes_indistinctus | -0.81        | .026                   |
clustered separately (PERMANOVA test, $P = .001$) and were more heterogeneous (Figure 2B). Antibiotic treatment in patients with COVID-19 was associated with a more heterogeneous microbiome configuration and accompanied by further shift of the gut microbiome away from a healthy microbiome (Figure 2B).

We next explored whether recovery from SARS-CoV-2 infection was associated with restoration of gut microbiome to a community level similar to that of healthy individuals. Overall, the gut microbiome of all patients with COVID-19 remained stable but were markedly disparate from that of healthy controls, both during the disease course and after clearance of SARS-CoV-2 (Figure 2C). Although the microbiome of 5 patients with COVID-19 (CoV1, 4, 7, 11, 15) showed closer proximity to healthy microbiomes over time, patients CoV3, 5, 8, 10, and 12 became more disparate from healthy microbiomes over time (Supplementary Figure 7). At the last follow-up, the gut microbiome of these 10 patients remained substantially different from that of healthy controls, despite clearance of SARS-CoV-2 infection as defined by negative SARS-CoV-2 tests on nasopharyngeal swab or deep throat saliva (Figure 2C, Supplementary Figure 7). Of note, patient CoV4 was discharged on day 5 but his gut microbiome on day 22 was persistently different from that of healthy individuals.

Baseline Gut Microbiome and Disease Severity of COVID-19

To understand whether baseline gut microbiome affects the severity of COVID-19, we assessed association between baseline fecal microbiome and COVID-19 severity (mild, moderate, severe, or critical) in 7 antibiotic-naïve COVID-19 cases. A total of 23 bacterial taxa were found to be significantly associated with COVID-19 disease severity, most of which (15 of 23) were from the Firmicutes phylum (Table 3). Among them, 8 and 7 Firmicutes members, respectively, showed positive and negative correlation with disease severity. These data are in line with a report showing that different Firmicutes bacteria have diverse roles in upregulating or downregulating ACE2 expression in the murine gut. Our finding of the association of gut Firmicutes bacteria with COVID-19 severity highlights the potential importance of bacterial membership in modulating human response to SARS-CoV-2 infection.

Three bacterial members from the Firmicutes phylum, the genus Coprobacillus, the species Clostridium ramosum and C. hathewayi, were the top bacteria positively associated with COVID-19 disease severity (Spearman correlation coefficient $Rho > 0.9$, $P < .01$, Table 3). Both C. ramosum and C. hathewayi have been associated with human infection and bacteremia. Importantly, Coprobacillus bacterium has been shown to strongly upregulate colonic expression of ACE2 in the murine gut. In contrast, 2 beneficial species, Alistipes onderdonkii and Faecalibacterium prausnitzii, were top bacterial species to show a negative correlation with COVID-19 severity (Table 3). Alistipes species are indole positive, involved in the serotonin precursor tryptophan metabolism and in maintaining gut immune homeostasis, whereas F. prausnitzii has anti-inflammatory properties. Although we cannot assign a causative or preventive role of these bacteria in disease pathogenesis or severity, our data underscore a potential role for bacteria in determining response to SARS-CoV-2 infection and intensity of the infection in the host.

Fecal SARS-CoV-2 Virus Load and Gut Bacterial Abundance

Eleven of the 15 patients had SARS-CoV-2 nucleic acid detected in feces at hospitalization (median 3.86 × 10$^3$ copies per mL inoculum, as determined by RT-PCR) and 5 of them cleared the SARS-CoV-2 virus over time (Figure 3A). We investigated whether gut bacteria were associated with fecal SARS-CoV-2 load over the course of hospitalization. A total of 14 bacterial species were identified to be
significantly associated with fecal viral load of SARS-CoV-2 across all fecal samples (Figure 3B). Among them, 6 species were from the Bacteroidetes phylum. Four Bacteroides species, including Bacteroides dorei, Bacteroides thetaiotaomicron, Bacteroides massiliensis, and Bacteroides ovatus, showed significant inverse correlation with fecal SARS-CoV-2 load (all Spearman correlation coefficient $Rho < -0.2$, $P < .05$, Figure 3B). Interestingly, all these 4 species were associated with downregulation of ACE2 expression in the murine colon.21 Taking together, these data suggest that Bacteroides species may have a potential protective role in combating SARS-CoV-2 infection by hampering host entry through ACE2. In contrast, Erysipelotrichaceae bacterium 2_2_44A, a Firmicutes species, showed the strongest positive correlation with fecal SARS-CoV-2 load (all Spearman correlation coefficient $Rho = 0.89$, $P = .006$, Figure 3B). Erysipelotrichaceae has been implicated in inflammation-related disorders of the GI tract.33 Considering the strong association of baseline abundance of Erysipelotrichaceae with COVID-19 severity (Spearman correlation Rho = 0.89, $P = .006$, Table 3), gut Erysipelotrichaceae may play a role in augmenting SARS-CoV-2 infection in the host gut.

Discussion

We showed for the first time that the gut microbiome was disturbed in patients with COVID-19. The alterations, observed even in patients with COVID-19 naïve to antibiotic therapy, were characterized by enrichment of opportunistic pathogens and depletion of beneficial commensals (Figure 4). Loss of salutary species in COVID-19 persisted in most patients despite clearance/recovery of SARS-CoV-2 virus, suggesting that exposure to SARS-CoV-2 infection and/or hospitalization may be associated with a more long-lasting detrimental effect to the gut microbiome.

Studies have shown that respiratory viral infections can alter the gut microbiome, such as pulmonary infections by influenza and respiratory syncytial virus.14,34–36 Viral infections predispose patients to secondary bacterial infections, which often have a more severe clinical course.14,37 We found that a number of pathogens and opportunistic pathogens were enriched in the gut microbiome of patients with COVID-19, including C. hathewayi, B. nordii, A. viscosus, and a higher baseline abundance of C. hathewayi correlated with more severe COVID-19. Most of these bacteria are bacteremia-associated bacteria, indicating susceptibility for severe disease course due to potential secondary bacterial infection. We also identified an opportunistic pathogen of the oral cavity and upper respiratory tract, A. viscosus, in the gut of patients with COVID-19.38 Its presence suggests the passage or transmission of extra-intestinal microbes into the gut.

Recently, a study provided direct evidence that SARS-CoV-2 can bind to human ACE2 as host entry point.3 ACE2
is highly expressed in the intestine especially in colonocytes of healthy subjects and in patients with inflammatory bowel disease, and can regulate amino acid transport, microbial ecology, and inflammation in the gut. Interestingly, Bacteroidetes species have been shown to downregulate ACE2 expression in the murine colon, whereas Firmicutes species showed variable effects in modulating ACE2 expression. We found that baseline abundance of Bacteroidetes species, A. onderdonkii and B. ovatus, negatively correlated with COVID-19 severity, and 4 species from the genus Bacteroides (B. dorei, B. thetaiotaomicron, B. massiliensis, and B. ovatus) showed inverse correlation with fecal viral load of SARS-CoV-2 (Figure 4). Among them, B. dorei has been reported to suppress colonic ACE2 expression and to calibrate host immune response. The highest SARS-CoV-2 mortality and morbidity have been reported in older patients and in those with underlying chronic diseases that are associated with inflammation, such as hypertension, obesity, diabetes mellitus, and coronary artery disease. Interestingly, these subjects were also reported to have a lower abundance of Bacteroides species than healthy individuals. These findings altogether suggest that an individual's gut microbiome configuration may affect the subject’s susceptibility and response to SARS-CoV-2 infection.

Cytokine profile associated with hyperinflammation state in severe COVID-19 has been characterized by increased interferon-γ inducible protein and other cytokines. Given limited proven treatment for COVID-19, understanding host cytokine pathways and microbiota interactions with cytokine responses in SARS-CoV-2 infection is essential in developing new treatment approaches.

One major limitation of this exploratory study is the modest sample size. Although assigning a causative relationship between COVID-19 and gut dysbiosis requires larger validation studies, this pilot study presents the first data to examine the influence of SARS-CoV2 infection on gut microbiome composition and dynamics. We attempted to adjust for factors, such as age, gender, therapy, and comorbidities, which may explain the observed variance in the data. As we included only hospitalized patients with moderate/severe disease, such findings may not be generalizable to all COVID-19 cases, including those with mild or asymptomatic COVID-19. Stool collected after hospitalization for microbiome analysis does not represent the baseline microbiome at COVID-19 onset, nor the baseline microbiome before disease onset. Further studies should prospectively include asymptomatic subjects, and if infected with SARS-CoV-2, followed up at disease onset, during disease course, and long term after discovery to delineate the role of microbiome changes in SARS-CoV-2 infection and postinfection recovery.

The use of empirical antibiotics (which was common in the initial outbreak of SARS-CoV-2 when secondary bacterial infection was a concern) led to further loss of salutary symbionts and exacerbation of gut dysbiosis in patients with COVID-19, and our data support avoidance of unnecessary antibiotics use in the treatment of viral pneumonitis, as antibiotics can eliminate beneficial bacteria and weaken the gut barrier. In addition, antibiotics-driven gut microbiome perturbation can alter immunity to vaccines in humans. Improving efficacy of future immune interventions such as vaccines, through modulating the gut microbiome, in combating COVID-19 should be considered. One approach for promoting a healthy microbiome may include measures to enhance intestinal butyrate production through the promotion of microbial interactions by dietary changes, and reduction of proinflammatory states.

In conclusion, our study provides evidence of prolonged gut microbiome dysbiosis in COVID-19 and its association with fecal SARS-CoV-2 virus shedding and disease severity. These data highlight a new concept that novel and targeted approach of modulation of the gut microbiota may represent a therapeutic avenue for COVID-19 and its comorbidities.

Supplementary Material
Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org, and at https://doi.org/10.1053/j.gastro.2020.05.048.

References
1. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy [published online ahead of print March 23, 2020]. JAMA. https://doi.org/10.1001/jama.2020.4683.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–513.
4. Liang W, Feng Z, Rao S, et al. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. Gut 2020;69:1141–1143.
5. Cheung KS, Hung IFN, Chan PPy, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis. Gastroenterology 2020;159:81–95.
6. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-19. Nature 2020;581:465–469.
7. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nature Medicine 2020;26:502–505.
8. Effenberger M, Grabherr F, Mayr L, et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut 2020;69:1543–1544.
9. Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020;581:221–224.
10. Wang J, Zhao S, Liu M, et al. ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism [published online
11. Xiao F, Tang M, Zheng X, et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020;158:1831–1833.e3.

12. Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 2012;487:477–481.

13. Ma W-T, Pang M, Fan Q-L, et al. The commensal microbiota and viral infection: a comprehensive review. Front Immunol 2019;10:1551.

14. Hanada S, Pirzadeh M, Carver KY, et al. Respiratory viral infection-induced Microbiome alterations and secondary bacterial pneumonia. Front Immunol 2018;9:2640.

15. Yildiz S, Mazel-Sanchez B, Kandasamy M, et al. Influenza A virus infection impacts systemic microbiota dynamics and causes quantitative enteric dysbiosis. Microbiome 2018;6:9.

16. Shen Z, Xiao Y, Kang L, et al. Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients. Clin Infect Dis 2020;71:713–720.

17. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027.

18. Emoto T, Yamashita T, Sasaki N, et al. Analysis of gut microbiota in coronary artery disease patients: a possible link between gut microbiota and coronary artery disease. Journal of atherosclerosis and thrombosis 2016;23:908–921.

19. Yang T, Santisteban MM, Rodriguez V, et al. Gut dysbiosis is linked to hypertension. Hypertension 2015;65:1331–1340.

20. Ley RE, Turnbaugh PJ, Klein S, et al. Human gut microbes associated with obesity. nature 2006;444:1022–1023.

21. Geva-Zatorsky N, Sefik E, Kua L, et al. Mining the human gut microbiota for immunomodulatory organisms. Cell 2017;168:928–943.e11.

22. Kalantar-Zadeh K, Ward SA, Kalantar-Zadeh K, et al. Considering the effects of microbiome and diet on SARS-CoV-2 infection: nanotechnology roles. ACS Nano 2020;14:5179–5182.

23. Wu J, Liu J, Zhao X, et al. Clinical characteristics of imported cases of COVID-19 in Jiangsu province: a multicenter descriptive study. Clin Infect Dis 2020;71:706–712.

24. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 2014;30:2114–2120.

25. Segata N, Waldron L, Ballarini A, et al. Metagenomic microbial community profiling using unique clade-specific marker genes. Nat Methods 2012;9:811.

26. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012;13:R79.

27. Elsayed S, Zhang K. Human infection caused by Clostridium hathewayi. Emerg Infect Dis 2004;10:1950.

28. Dakshinamurthy M, Venkatesh A, Arumugam K. A literature review on dental caries vaccine—a prevention strategy. Indian J Public Health 2019;10:3041–3043.

29. Forrester JD, Spain DA. Clostridium ramosum bacteria: case report and literature review. Surg Infect 2014;15:343–346.

30. Gao J, Xu K, Liu H, et al. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front Cell Infect Microbiol 2018;8:13.

31. Verdu EF, Hayes CL, O’Mahony SM. Importance of the microbiota in early life and influence on future health. In: The Gut-Brain Axis. London: Elsevier, 2016:159–184.

32. Miquel S, Martin R, Rossi O, et al. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol 2013;16:255–261.

33. Kaakoush NO. Insights into the role of Erysipelothrix in the human host. Front Cell Infect Microbiol 2015;5:84.

34. Wang J, Li F, Wei H, et al. Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell–dependent inflammation. J Exp Med 2014;211:2397–2410.

35. Deriu E, Boxx GM, He X, et al. Influenza virus affects intestinal microbiota and secondary salmonella infection in the gut through type I interferons. PLoS Pathog 2016;12:e1005572.

36. Groves HT, Cuthbertson L, James P, et al. Respiratory disease following viral lung infection alters the murine gut microbiota. Front Immunol 2018;9:182.

37. Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis 2006;6:303–312.

38. Habib S, Siddiqui AH, Azam M, et al. Actinomyces viscosus causing disseminated disease in a patient on methotrexate. Respir Med Case Rep 2018;25:158–160.

39. Vatanen T, Kostic AD, d’Hennezel E, et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell 2016;165:842–853.

40. Yoshida N, Emoto T, Yamashita T, et al. Bacteroides vulgatus and Bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis. Circulation 2018;138:2486–2498.

41. Qinxian C, Fengjuan C, Wang T, et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care 2020;43:1392–1398.

42. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8:e21.

43. Hill MA, Mantzoros C, Sowers JR. Commentary: COVID-19 in patients with diabetes. Metabolism 2020;107:154217.

44. Mendes V, Galvao I, Vieira AT. Mechanisms by which the gut microbiota influences cytokine production and modulates host inflammatory responses. J Interferon Cytokine Res 2019;39:393–409.

45. Tustrup MV-L, Christensen EG, Carvalho V, et al. Anti-biotic treatment affects intestinal permeability and gut microbial composition in Wistar rats dependent on anti-biotic class. PLoS One 2015;10:e0144854.

46. Hagan T, Cortese M, Rouphael N, et al. Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans. Cell 2019;178:1313–1328.e13.
Author names in bold designate shared co-first authorship.

Received May 4, 2020. Accepted May 14, 2020.

Correspondence
Address correspondence to: Siew C. Ng, PhD, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 9/F, Lui Che Woo Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong. e-mail: siewchienng@cuhk.edu.hk; fax: (852) 3505 3852; or Paul K.S. Chan, PhD, Department of Microbiology, The Chinese University of Hong Kong, 9/F, Lui Che Woo Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong. e-mail: paulkschan@cuhk.edu.hk; fax: (852) 2647 3227.

Acknowledgments
We thank all health care workers working in isolation wards of Prince of Wales Hospital, Hong Kong, China. We thank Apple C.M. Yeung, Wendy C.S. Ho, Miu L. Chin, Rity Wong, and Vickie Li for their technical contributions in this study. We thank Whitney Tang for her assistance with the graphical abstract.

CRediT Authorship Contributions
Tao Zuo, PhD (Formal analysis: Lead; Investigation: Equal; Methodology: Lead; Writing – original draft: Lead; Writing – review & editing: Lead). Fen Zhang, PhD (Formal analysis: Equal; Methodology: Equal). Grace C.Y. Lui, Dr (Conceptualization: Equal; Resources: Lead; Writing – review & editing: Equal). Yun Kit Yeoh, PhD (Writing – review & editing: Lead). Amy Y.L. Li, Bachelor (Data curation: Lead). Hui Zhan, PhD (Investigation: Supporting). Yating Wan, PhD (Methodology: Supporting). Arthur Chung, PhD (Methodology: Supporting). Chun Peng Cheung, Bachelor (Project administration: Lead). Nan Chen, Master (Investigation: Supporting). Christopher K.C. Lai, PhD (Writing – review & editing: Supporting). Zigui Chen, PhD (Writing – review & editing: Equal). Eugene Y.K. Tso, MD (Resources: Equal). Kitty S.C. Fung, MD (Resources: Equal). Veronica Chan, MD (Resources: Equal). Lowell Ling, MD (Resources: Equal). Gavin Joynt, PhD (Supervision: Supporting). David S.C. Hui, MD (Supervision: Supporting). Francis K.L. Chan, MD (Supervision: Lead). Paul K.S. Chan, PhD (Project administration: Lead). Siew C. Ng, PhD (Conceptualization: Lead; Funding acquisition: Lead; Resources: Lead; Supervision: Lead; Writing – review & editing: Lead).

Conflict of interest
The authors disclose no conflicts.

Funding
This study was funded by D. H. Chen Foundation and Health and Medical Research Fund, Hong Kong.
Supplementary Figure 1. Longitudinal changes of fecal abundance of *Eubacterium ventriosum* in patients with COVID-19 over the disease course. Bacterial species abundance is expressed as fractional abundance (%). “D0” denotes baseline date when the first stool was collected after hospitalization; the following timepoints starting with “D” represent days since baseline stool collection.
Supplementary Figure 2. Longitudinal changes of fecal abundance of *Dorea formicigenerans* in patients with COVID-19 over the disease course. Bacterial species abundance is expressed as fractional abundance (%). “D0” denotes baseline date when the first stool was collected after hospitalization; the following timepoints starting with “D” represent days since baseline stool collection.
Supplementary Figure 3. Longitudinal changes of fecal abundance of *Faecalibacterium prausnitzii* in patients with COVID-19 over the disease course. Bacterial species abundance is expressed as fractional abundance (%). “D0” denotes baseline date when the first stool was collected after hospitalization; the following timepoints starting with “D” represent days since baseline stool collection.
Supplementary Figure 4. Longitudinal changes of fecal abundance of *Eubacterium rectale* in patients with COVID-19 over the disease course. Bacterial species abundance is expressed as fractional abundance (%). “D0” denotes baseline date when the first stool was collected after hospitalization; the following timepoints starting with “D” represent days since baseline stool collection.
Supplementary Figure 5. Longitudinal changes of fecal abundance of *Ruminococcus obeum* in patients with COVID-19 over the disease course. Bacterial species abundance is expressed as fractional abundance (%). “D0” denotes baseline date when the first stool was collected after hospitalization; the following timepoints starting with “D” represent days since baseline stool collection.
Supplementary Figure 6. Longitudinal changes of fecal abundance of *Lachnospiraceae bacterium_5_1_63F AA* in patients with COVID-19 over the disease course. Bacterial species abundance is expressed as fractional abundance (%). “D0” denotes baseline date when the first stool was collected after hospitalization; the following timepoints starting with “D” represent days since baseline stool collection.
Supplementary Figure 7. Longitudinal changes of the fecal microbiome in patients with COVID-19, at the community level, during the disease course. “CoV” denotes patient with COVID-19. “D0” denotes baseline date when the first stool was collected after hospitalization; the following timepoints starting with “D” represent days since baseline stool collection.
| Case | Sex | Age | Comorbidities | Recent exposure history | Symptoms at admission | Admitted to ICU | Chest radiograph findings | COVID-19 severity |
|------|-----|-----|---------------|-------------------------|-----------------------|-----------------|--------------------------|------------------|
| CoV1 | F   | 65  | Hypertension, Chronic hepatitis B carrier | No | Fever, cough, sputum | Nil | Yes | Bilateral LZ haziness | Critical |
| CoV2 | F   | 55  | None | Contact with person with COVID-19 | Fever, runny nose | Nil | No | Bilateral LZ haziness | Moderate |
| CoV3 | M   | 42  | None | Travel to Hubei province | Fever, cough | Nil | Yes | RLZ haziness, RLL collapse | Critical |
| CoV4 | M   | 70  | Hyperlipidemia, duodenal ulcer | No | Cough, shortness of breath | Nil | No | Bilateral lung haziness | Severe |
| CoV5 | M   | 58  | None | Contact with person with COVID-19 | Fever, cough | Diarrhea | No | Slight RLZ haziness | Moderate |
| CoV6 | M   | 71  | None | | Fever, cough, shortness of breath | Nil | No | Bilateral lung infiltration | Severe |
| CoV7 | M   | 48  | Diabetes mellitus, hypertension, hyperlipidemia | No | Fever, cough | Nil | No | LLZ haziness | Moderate |
| CoV8 | F   | 38  | None | | | Nil | No | Bilateral LZ infiltrates | Moderate |
| CoV9 | M   | 33  | None | Contact with person with COVID-19 | Fever, cough | Nil | No | Bilateral LZ haziness | Moderate |
| CoV10| F   | 70  | Obesity, hypertension | No | Cough | Nil | No | Bilateral LZ haziness | Moderate |
| CoV11| M   | 62  | Diabetes, hyperlipidemia, left subclavian artery occlusion | No | Fever, cough, sputum, shortness of breath | Nil | No | Bilateral lung infiltrates | Severe |
| CoV12| F   | 71  | Hypertension, renal impairment, hyperlipidemia | Contact with person with COVID-19 | Cough | Nil | No | Bilateral lung infiltrates | Moderate |
| CoV13| F   | 47  | None | Contact with person with COVID-19 | Cough | Nil | No | Bilateral lung infiltrates | Moderate |
| CoV14| F   | 22  | None | Contact with person with COVID-19 | Fever, runny nose | Nil | No | Bilateral lung infiltrates | Moderate |
| CoV15| F   | 46  | None | Contact with person with COVID-19 | Cough, shortness of breath | Nil | No | Clear | Mild |
| P1   | F   | 69  | Hypertension, diabetes mellitus, Tricuspid regurgitation | No | Fever | Nil | No | LMZ pneumonia | N/A |
| P2   | M   | 43  | Nonalcoholic Fatty liver disease | No | Cough | Nil | No | Right sided infiltrates | N/A |
| P3   | F   | 92  | Diabetes, Hypertension, pulmonary fibrosis, Paroxysmal atrial fibrillation, Acute coronary syndrome | No | Cough, sputum, shortness of breath | Nil | No | Bilateral lung infiltrate | N/A |
| P4   | M   | 47  | Diabetes mellitus | No | Fever, sputum | Nil | No | Left effusion, LMZ infiltrates | N/A |
| P5   | M   | 36  | Ischemic priapism | No | Fever, cough, sputum, shortness of breath | Diarrhea | No | N/A | N/A |
| P6   | M   | 52  | Epilepsy, Hepatitis | No | Fever, cough, runny nose, shortness of breath | Diarrhea | No | N/A | N/A |

LLZ, left lower zone; LMZ, left middle zone; N/A, not applicable.